The results of the PROWESS SHOCK test showed that drotrecogin alfa had no benefit in patients with sepsis.[42] Subsequently, recombinant human activated protein C was withdrawn from the market, but the trial included patients with sepsis, not just patients with SPG secondary to sepsis. Here, PROC is linked to Sepsis.